
Uppsala Reports editor
@UMCGlobalSafety
In this digital age, can pharmacovigilance experts leverage on new types of data to find evidence for signals? Listen to the latest Drug Safety Matters podcast to find out.
Spontaneous adverse drug reaction reports have been the proverbial ‘bread and butter’ for signal detection since the beginnings of pharmacovigilance. But times are changing, and with the abundance of data now available in a society that has gone digital, so it is time to explore new data sources to detect signals.
Join Federica Santoro and Daniele Sartori, a pharmacovigilance scientist at UMC and doctoral researcher at the University of Oxford, discuss expanding sources of evidence for more reliable signal detection.
Subscribe by visiting the Drug Safety Matters website or listen to the podcast here:
In a weeklong groundbreaking study-a-thon with the IMI EHDEN consortium, UMC researchers found longitudinal health data could boost preliminary analysis of drug-event combinations.
Research / 28 October 2022
The Research corner film series puts UMC pharmacovigilance scientists in the spotlight as they discuss their research and its implications for pharmacovigilance science.
Research / 16 March 2023
First came the COVID-19 pandemic. Then came the COVID-19 vaccines. Then came millions of COVID-19 vaccine reports of suspected side effects. What are the implications of that?
Research / 25 November 2022